SciELO - Scientific Electronic Library Online

 
vol.110 número8Dispepsia, dispepsia funcional y criterios de Roma IVAdenoma tubular de íleon como causa de sangrado intestinal bajo en lactante menor índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google

Compartir


Revista Española de Enfermedades Digestivas

versión impresa ISSN 1130-0108

Rev. esp. enferm. dig. vol.110 no.8 Madrid ago. 2018

https://dx.doi.org/10.17235/reed.2018.5588/2018 

LETTERS

A pneumoperitoneum due to intestinal cystic pneumatosis associated with a tyrosine kinase inhibitor

Alicia Martín-Lagos-Maldonado1  , Cristina Lozano-Cejudo2  , Antonio Sáenz-Lozano3 

1Servicio de Aparato Digestivo. Hospital Campus de la Salud de Granada. Granada, Spain

2Servicio de Radiodiagnóstico. Hospital General Universitario de Ciudad Real. Ciudad Real, Spain

3Servicio de Medicina Interna. Hospital Virgen de Altagracia. Manzanares, Ciudad Real, Spain

Key words: Intestinal pneumatosis; Pneumoperitoneum. Molecular therapy; Bowel toxicity; Tyrosine kinase

Dear Editor,

Pneumatosis cystoides intestinalis is characterized by multiple air-filled cysts in the intestine wall. Recently, antitumor molecular targeted therapies have been associated with bowel perforation and the development of secondary pneumoperitoneum.

Case report

We present the case of a 72-year-old male that had undergone a right nefrectomy due to a renal cell carcinoma in 2010. He was currently receiving chemotherapy for lung metastasis (pazopanib, a tyrosine kinase inhibitor). A computed tomography (CT) scan showed air-filled cysts in the right colon wall, which was suggestive of an intestinal cystic pneumatosis. Furthermore, import free air was also present due to secondary pneumoperitoneum (Fig. 1). The patient presented to the Emergency Department. However, due to the absence of symptoms, clinical peritonitis or analytical impact, an observational control with a liquid diet therapy and intravenous antibiotics was performed. The patients' course was favorable, and a radiologic examination ten days later showed that the condition had been resolved. After medical discharge, treatment with nivolumab was started, as a substitute to pazopanib.

Fig. 1 TC abdominal. A. A clip that corresponds to the complete nefrectomy is seen in the right perirenal space. B. The green arrows indicate the air-filled cysts in the colonic wall that indicate cystic pneumatosis. The pink arrows indicate air secondary to a pneumoperitoneum. 

Discussion

Pneumoperitoneum secondary to intestinal pneumatosis is an unusual complication and often has minimal clinical repercussions. Its etiology seems to be multifactorial and is thought to be a sign of bowel toxicity with antitumor therapy. Recently, De la Serna et al. reported the association with cytostatic and molecular targeted therapies (bevacizumab) 1. Tyrosine kinase inhibitors are another pharmacological group that are associated with this complication 2,3. In the majority of cases, pneumoperitoneum secondary to cystic pneumatosis does not require surgical treatment at first and can be managed conservatively. The presence of intestinal pneumatosis during treatment for cancer is difficult to interpret. Therefore, it is important to establish any relationship with clinical findings 4. The evolution described in the literature is variable and the effect of these drugs is inexplicable.

Bibliografía

1. De la Serna S, Luna A, De la Rosa H. Neumatosis intestinal y neumoperitoneo en contexto de tratamiento oncológico: un cambio de actitud. Rev Esp Enferm Dig 2018:110(1):68-9. [ Links ]

2. Shinagare A, Howard S, Krajewski K, et al. Pneumatosis intestinalis and bowel perforation associated with molecular targeted therapy: an emerging problem and the role of radiologists in its management. AJR Am J Roentgenol 2012;199(6):1259-65. DOI: 10.2214/AJR.12.8782 [ Links ]

3. Flaig TW, Kim FJ, La Rosa FG, et al. Colonic pneumatosis and intestinal perforations with sunitinib treatment for renal cell carcinoma. Invest New Drugs 2009;27(1):83-7. DOI: 10.1007/s10637-008-9146-z [ Links ]

4. Choi YA, Sim EH, Lee KE, et al. A case of pneumatosis intestinalis associated with sunitinib treatment for renal cell carcinoma. Korean J Gastroenterol 2013;61(6):347-50. DOI: 10.4166/kjg.2013.61.6.347 [ Links ]

Creative Commons License Este es un artículo publicado en acceso abierto bajo una licencia Creative Commons